Investigation of transport mechanism of exendin-4 across Madin Darby canine kidney cell monolayers

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 5, 2012, Pages 745-752

  Wang, Mengshu ^a   Sun, Bingxue ^a   Feng, Jiao ^a   Zhang, Haihong ^a   Liu, Bin ^b   Li, Chun ^a   Chen, Yan ^a   Zhang, Yong ^a   Kong, Wei ^a  

^a JILIN UNIVERSITY   (China)

^b Jilin Product Quality Supervision Inspection   (China)

Author keywords

Absorption; Enhancer; Paracellular transport; Peptide; Transepithelial transport mechanism

Indexed keywords

BIOLOGICAL MARKER; CHITOSAN; EDETIC ACID; EXENDIN 4;

ANIMAL CELL; ARTICLE; CELL MEMBRANE PERMEABILITY; CONCENTRATION (PARAMETERS); CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY TEST; DOG; DRUG FORMULATION; DRUG TRANSPORT; ENERGY TRANSFER; HYDROPHILICITY; INTESTINE ABSORPTION; INTRACELLULAR SIGNALING; KIDNEY CELL CULTURE; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN DETERMINATION; TEMPERATURE SENSITIVITY; TIGHT JUNCTION;

ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE; CHITOSAN; DECANOIC ACIDS; DOGS; EDETIC ACID; HUMANS; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; KIDNEY; PEPTIDES; PERMEABILITY; VENOMS;

EID: 84861207593     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.35.745     Document Type: Article

References (34)

1. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG, GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann. Intern. Med., 143, 559-569 (2005).
2. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care, 28, 1092-1100 (2005).
3. Nielsen LL. Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. Drug Discov. Today, 10, 703-710 (2005).
4. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J. Biol. Chem., 267, 7402-7405 (1992).
5. Nauck MA. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. Horm. Metab. Res., 36, 852-858 (2004).
6. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD, Exenatide- 113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care, 27, 2628-2635 (2004).
7. Hargrove DM, Kendall ES, Reynolds JM, Lwin AN, Herich JP, Smith PA, Gedulin BR, Flanagan SD, Jodka CM, Hoyt JA, McCowen KM, Parkes DG, Anderson CM. Biological activity of AC3174, a peptide analog of exendin-4. Regul. Pept., 141, 113-119 (2007).
8. Gedulin BR, Smith PA, Jodka CM, Chen K, Bhavsar S, Nielsen LL, Parkes DG, Young AA. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration. Int. J. Pharm., 356, 231-238 (2008).
9. Khafagy El-S, Morishita M, Kamei N, Eda Y, Ikeno Y, Takayama K. Efficiency of cell-penetrating peptides on the nasal and intestinal absorption of therapeutic peptides and proteins. Int. J. Pharm., 381, 49-55 (2009).
10. Sakuma S, Suita M, Masaoka Y, Kataoka M, Nakajima N, Shinkai N, Yamauchi H, Hiwatari K, Tachikawa H, Kimura R, Yamashita S. Oligoarginine-linked polymers as a new class of penetration enhancers. J. Control. Release, 148, 187-196 (2010).
11. Khafagy El-S, Morishita M, Takayama K. The role of intermolecular interactions with penetratin and its analogue on the enhancement of absorption of nasal therapeutic peptides. Int. J. Pharm., 388, 209-212 (2010).
12. Jin CH, Chae SY, Son S, Kim TH, Um KA, Youn YS, Lee S, Lee KC. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice. J. Control. Release, 133, 172-177 (2009).
13. Nguyen HN, Wey SP, Juang JH, Sonaje K, Ho YC, Chuang EY, Hsu CW, Yen TC, Lin KJ, Sung HW. The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo. Biomaterials, 32, 2673-2682 (2011).
14. Ma B, Zha H, Li N, Yang D, Lin G. Effect of structural modification of α-aminoxy peptides on their intestinal absorption and transport mechanism. Mol. Pharm., 8, 1073-1082 (2011).
15. Kehler JR, Bowen CL, Boram SL, Evans CA. Application of DBS for quantitative assessment of the peptide exendin-4; comparison of plasma and DBS method by UHPLC-MS/MS. Bioanalysis, 2, 1461-1468 (2010).
16. Varma MV, Kapoor N, Sarkar M, Panchagnula R. Simultaneous determination of digoxin and permeability markers in rat in situ intestinal perfusion samples by RP-HPLC. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 813, 347-352 (2004).
17. Venkatesh G, Ramanathan S, Mansor SM, Nair NK, Sattar MA, Croft SL, Navaratnam V. Development and validation of RP-HPLCUV method for simultaneous determination of buparvaquone, atenolol, propranolol, quinidine and verapamil: a tool for the standardization of rat in situ intestinal permeability studies. J. Pharm. Biomed. Anal., 43, 1546-1551 (2007).
18. Gan LS, Hsyu PH, Pritchard JF, Thakker D. Mechanism of intestinal absorption of ranitidine and ondansetron: transport across Caco- 2 cell monolayers. Pharm. Res., 10, 1722-1725 (1993).
19. Stetinová V, Smetanová L, Kholová D, Svoboda Z, Kvetina J. Transepithelial transport of ambroxol hydrochloride across human intestinal Caco-2 cell monolayers. Gen. Physiol. Biophys., 28, 309-315 (2009).
20. Ménez C, Buyse M, Dugave C, Farinotti R, Barratt G. Intestinal absorption of miltefosine: contribution of passive paracellular transport. Pharm. Res., 24, 546-554 (2007).
21. Braun A, Hämmerle S, Suda K, Rothen-Rutishauser B, Günthert M, Krämer SD, Wunderli-Allenspach H. Cell cultures as tools in biopharmacy. Eur. J. Pharm. Sci., 11 (Suppl. 2), S51-S60 (2000).
22. Kwak HH, Shim WS, Son MK, Kim YJ, Kim TH, Youn HJ, Kang SH, Shim CK. Efficacy of a new sustained-release microsphere formulation of exenatide, DA-3091, in Zucker diabetic fatty (ZDF) rats. Eur. J. Pharm. Sci., 40, 103-109 (2010).
23. Kwak HH, Shim WS, Hwang S, Son MK, Kim YJ, Kim TH, Yoon ZH, Youn HJ, Lee GI, Kang SH, Shim CK. Pharmacokinetics and efficacy of a biweekly dosage formulation of exenatide in Zucker diabetic fatty (ZDF) rats. Pharm. Res., 26, 2504-2512 (2009).
24. Morishita M, Kamei N, Ehara J, Isowa K, Takayama K. A novel approach using functional peptides for efficient intestinal absorption of insulin. J. Control. Release, 118, 177-184 (2007).
25. Morishita M, Peppas NA. Is the oral route possible for peptide and protein drug delivery? Drug Discov. Today, 11, 905-910 (2006).
26. Hidalgo IJ. Assessing the absorption of new pharmaceuticals. Curr. Top. Med. Chem., 1, 385-401 (2001).
27. Shah P, Jogani V, Bagchi T, Misra A. Role of Caco-2 cell monolayers in prediction of intestinal drug absorption. Biotechnol. Prog., 22, 186-198 (2006).
28. Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR Jr. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J. Pharm. Sci., 88, 28-33 (1999).
29. Volpe DA. Variability in Caco-2 and MDCK cell-based intestinal permeability assays. J. Pharm. Sci., 97, 712-725 (2008).
30. Kamei N, Morishita M, Takayama K. Importance of intermolecular interaction on the improvement of intestinal therapeutic peptide/ protein absorption using cell-penetrating peptides. J. Control. Release, 136, 179-186 (2009).
31. Körner M, Stöckli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J. Nucl. Med., 48, 736-743 (2007).
32. Tamai I. Oral drug delivery utilizing intestinal OATP transporters. Adv. Drug Deliv. Rev., 64, 508-514 (2011).
33. Liang JF, Yang VC. Insulin-cell penetrating peptide hybrids with improved intestinal absorption efficiency. Biochem. Biophys. Res. Commun., 335, 734-738 (2005).
34. Ward PD, Tippin TK, Thakker DR. Enhancing paracellular permeability by modulating epithelial tight junctions. Pharm. Sci. Technol. Today, 3, 346-358 (2000).